NASDAQ: TVRDTvardi Therapeutics Inc Stock
$4.97-0.19 (-3.68%)
Updated Oct 24, 2025
TVRD Price
$4.97
Fair Value Price
N/A
Market Cap
$46.61M
52 Week Low
$4.90
52 Week High
$43.65
P/E
-0.31x
P/B
1.42x
P/S
29.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.58M
Earnings
-$20.89M
Gross Margin
100%
Operating Margin
-210.4%
Profit Margin
-317.5%
Debt to Equity
0.33
Operating Cash Flow
-$32M
Beta
0.92
Next Earnings
Nov 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TVRD Overview
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TVRD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TVRD
Ranked#366 of 486
Ranked#366 of 486
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.28 | A | |
| $11.89 | A | |
| $7.20 | A |
Be the first to know about important TVRD news, forecast changes, insider trades & much more!
TVRD News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TVRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TVRD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TVRD is good value based on its book value relative to its share price (1.42x), compared to the US Biotechnology industry average (4.92x)
P/B vs Industry Valuation
TVRD is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TVRD due diligence checks available for Premium users.
Valuation
TVRD fair value
Fair Value of TVRD stock based on Discounted Cash Flow (DCF)
Price
$4.97
Fair Value
-$14.28
Undervalued by
134.80%
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TVRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.31x
Industry
-88.22x
Market
38.91x
TVRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
4.92x
TVRD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TVRD's financial health
Profit margin
Revenue
$0.0
Net Income
$4.2M
Profit Margin
0%
TVRD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TVRD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$43.8M
Liabilities
$10.8M
Debt to equity
0.33
TVRD's short-term assets ($43.13M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVRD's short-term assets ($43.13M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVRD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TVRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
-$20.4M
Financing
$22.0M
TVRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TVRD vs Biotech Stocks
Tvardi Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.